Office: Room 103 3609 Forbes Avenue, 15213

Phone: 412-648-3012



Inmaculada (Inma) Hernandez joined the faculty of the University of Pittsburgh in 2016, where she serves as an Assistant Professor of Pharmacy and Therapeutics and as Associate Director of the Center for Pharmaceutical Policy and Prescribing. Dr. Hernandez has published over 35 peer-reviewed manuscripts, including 23 as first-author and 7 as senior author. These articles have been published in top-tier medical journals, including Annals of Internal Medicine, JAMA Internal Medicine, JAMA Oncology, Health Affairs, and Stroke, and have been featured in the main media outlets, including NPR, Forbes, ABC, CNBC, Fox News, Bloomberg, or USA Today. Hernandez was recently awarded a K01 career development award from the National Heart, Lung and Blood Institute to study patient and system-level determinants of oral anticoagulation use in atrial fibrillation (K01HL142847). She is also the PI of a small grant from the Alzheimer’s Association on the use of data mining techniques to predict side effects of anti-dementia drugs (AARGD-17-500234). She was recently recognized on the Forbes 30 under 30 list as a young leader in healthcare research. She also serves as Associate Editor for the journal BMC Cardiovascular Disorders.
Hernandez’s research program is built at the intersection of pharmaceutical health services and outcomes research, pharmacoepidemiology, pharmacoeconomics and pharmaceutical policy. Specifically, her current research has 3 main areas of focus:
• Real-world use and outcomes of oral anticoagulation therapy in stroke prevention in atrial fibrillation.
• Use of large data sets, advanced data mining techniques and comparative effectiveness research to predict and compare outcomes of antidementia medications.
• Study of pharmaceutical pricing trends and pricing strategies in response to market disruptions.

Dr. Hernandez earned her PharmD from the University of Navarra (Spain) in 2013, and she completed her clinical training in the North Middlesex University Hospital and Green Light Pharmacy, both in London (UK). Upon graduation, she was selected as 1 in 48 among thousands of graduates in Spain across all disciplines to receive a “La Caixa” fellowship. This prestigious fellowship supported her PhD studies in Health Services Research and Policy at the University of Pittsburgh Graduate School of Public Health. Completed in 3 years, the research conducted during her PhD yielded 11 first-author peer-reviewed publications and 2 press releases. Published in JAMA Internal Medicine and Stroke, some of these studies were among the first to provide evidence on the real-world outcomes of non-vitamin K antagonist oral anticoagulants after their approval, and were featured in media outlets around the world.

(For a complete list of publications, please see links to ORCID or my NCBI bibliography on the left)


Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of Bleeding with Dabigatran in Atrial Fibrillation. JAMA Intern Med. 2015; 175(1):18-24.

Hernandez I, Zhang Y. Risk of Bleeding with Dabigatran in 2010-2011 Medicare Data. JAMA Intern Med. 2015; 175(7):1245-7

Hernandez I, Zhang Y, Brooks M, Chin P, Saba S. Anticoagulation Use and Clinical Outcomes Following Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation. Stroke 2017: 48 (1) 159-166

Hernandez I, Saba S, Zhang Y. Geographic Variation in the Use of Oral Anticoagulation Therapy in Atrial Fibrillation. Stroke 2017; 48(1)2289-2281.

Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drug 2017; 17(1):37-47.

Hernandez I, Smith K, Zhang Y. Cost-Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation at High Risk of Bleeding and Normal Kidney Function. Thromb Res 2017: 123-130

Hernandez I, Zhang Y, Saba S. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban and Warfarin in Newly Diagnosed Atrial Fibrillation. Am J Cardiol. 2017;120(10):1813-1819.

Hernandez I, Zhang Y, Saba S. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients with Atrial Fibrillation. Am J Cardiol. 2018;122(1):69-75.


Hernandez I, Good CB, Cutler DM, Gellad WF, Parekh N, Shrank WH. The Contribution of New Product Innovation vs Existing Product Inflation in the Rising Costs of Prescription Drugs. Health Affairs. 2019; 38(1): 76-83

Hernandez I. Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab. JAMA Intern Med 2017;177(9):1388-1390

Hernandez I, Prasad V, Gellad WF. The True Costs of Chimeric Antigen Receptor T-Cell Therapy. JAMA Oncol. 2018 doi:10.1001/jamaoncol.2018.0977

Hernandez I, Sampathkumar S*, Good CB, He M, Kesselheim AS, Shrank WH. Changes in Drug Pricing After Drug Shortages in the US. Ann Intern Med. 2018 doi: 10.7326/M18-1137

San-Juan-Rodriguez A*, Prokopovich MP*, Shrank WH, Good CB, Hernandez I. Changes in the Prices of Incumbent TNF-alpha Inhibitors Following the Market Entry of Competitors. JAMA Intern Med. In press

Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S and Shrank WH. Pricing of Monoclonal Antibody Therapies in the US: Higher if Used for Cancer? Am J Manag Care. 2018;24(2):294-297


Hernandez I, He M, Brooks, MM, Zhang Y. Exposure-Response Association between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries. JAMA Network Open. 2018: 1(2):e180919.

Hernandez I, He M, Zhang Y. Comparing State, Regional, and Local Variation in Concurrent Opioid and Benzodiazepine Use. Drug Alcohol Depend. 2018; 191:141-144

Hernandez I, Zhang Y. Using Predictive Analytics and Big Data in Optimizing Pharmaceutical Outcomes. Am J Health Syst Pharm. 2017;74(18):1494-1500

Hernandez I, Zhang Y. Comparing Clinical and Economic Outcomes of Biologic and Conventional Medications in Postmenopausal Women with Osteoporosis. J Eval Clin Pract. 2015; 21(5):840-7

Hernandez, I. Risk Factors for Cardiovascular Events of Anti-dementia Drugs in Alzheimer’s disease patients. J Clin Gerontol Geriatr 2016; 7(3):77-82.

MENTEE’S PUBLICATIONS (* denotes work from student/postdoctoral advisees)

San-Juan-Rodriguez A*, Prokopovich MP*, Shrank WH, Good CB, Hernandez I. Changes in the Prices of Incumbent TNF-alpha Inhibitors Following the Market Entry of Competitors. JAMA Intern Med. In Press

Hernandez I, Sampathkumar S*, Good CB, He M, Kesselheim AS, Shrank WH. Changes in Drug Pricing After Drug Shortages in the US. Ann Intern Med. 2018 doi: 10.7326/M18-1137

Gray MP*, Saba S, Zhang Y, Hernandez I. Outcomes of Atrial Fibrillation Patients Newly Recommended for Oral Anticoagulation under the 2014 AHA/ACC/HRS Guideline. J Am Heart Assoc. 2017;6:e007881.

Hospodar A*, Smith KJ, Zhang Y, Hernandez I. Comparing the Cost-effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants with Well-managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. Am J Cardiovasc Drugs. doi: 10.1007/s40256-018-0279-y27.

San-Juan-Rodriguez A*, Zhang Y, He M, Hernandez I. Association of Antidementia Therapies with Time to Skilled Nursing Facility Admission and Cardiovascular Events among Elderly Adults with Alzheimer Disease. JAMA Network Open. In press

Wolf C*, Bott S*, Hernandez I, Grieve L. Investing in the Future Teaching about the Healthcare Industry through Gamification. Am J Pharm Educ. 2018;82(4). doi:org/10.5688/ajpe6422

1.“La Caixa” Foundation Fellowship 2013 (1 in 48 selected in Spain in 2013 to receive full tuition and stipend support to pursue Graduate Studies in North America).

2. Excellence Award First of the Pharmacy Class 2013, University of Navarra.

3. American Heart Association 2016 Fellows Research Day 1st Place Award (Clinical Science Category).

4. PCORI/AHA Challenge Comparative Effectiveness Research and Precision Medicine Approaches for Heart Disease and Stroke Treatment Research and Clinician Challenge Award, December 2016 (1 in 4 selected among 200 submissions).

5. Delta Omega National Public Health Honor Society Omicron Chapter Best Doctoral Dissertation Award, April 2017

6. Top 3 Nationwide Pharmacy School 2013 Graduate, Spanish Department of Education, May 2017.

7. Top 5 most cited JAMA Internal Medicine papers in the last 3 years for “Risk of Bleeding with Dabigatran in Atrial Fibrillation”, 2017 (first author).

8. Top Peer Reviewer in 2017 for the Journal Pharmacoepidemiology and Drug Safety, August 2018.

9. Senior author and research mentor for the paper “Outcomes of Atrial Fibrillation Patients Newly Recommended for Oral Anticoagulation under the 2014 AHA/ACC/HRS Guideline”, awarded the 2018 ASHP Student Research Paper Award of the Year, December 2018.

10. Fellow, American College of Cardiology, September 2018.

11. Highest-quality 2017 Peer Reviewer for the Journal of Managed Care and Specialty Pharmacy, September 2018.

12. 30 Under 30 Forbes list maker, Healthcare category. Class of 2019. Forbes Magazine, November 2018.

1. Patient and System-Level Determinants of Oral Anticoagulation Use in Atrial Fibrillation (1K01HL142847-01). Founding Agency: NHLBI. Direct costs: $733,147. Effort supported: 9 cal. Principal Investigator (Sole). Funding Period: 07/15/2018-06/30/2023.
2. Claims Data Mining to Predict Side Effects of Anti-dementia Drugs (AARGD-17-500234). Founding Agency: Alzheimer’s Association. Direct costs: $135,805. Effort supported: 3.1 cal. Role: Principal Investigator (Sole). Funding Period: 03/01/2017-02/28/2020.

1. Impact of Community Pharmacists. Founding Agency: National Association of Chain Drug Stores (NACDS). Direct costs: $58,335. Effort supported: 2.2 cal. Role: Co-Investigator (PI of Subcontract). Funding Period: 10/01/2017-03/31/2018.